Regulation of transferrin receptor 2 in human cancer cell lines.
In a recent study we have explored TfR2 expression in a panel of cancer cell lines and we observed that about 40% of these cell lines clearly express TfR2. Taking advantage of this observation and considering the frequent overexpression of c-Myc in cancer cells we have explored the existence of a possible relationship between c-Myc and TfR2 in these cell lines. Our results provided evidence that TfR2(+) cell lines express low c-Myc levels and low TfR1 levels, while TfR2(-) cell lines express high c-Myc and TfR1 levels. Using the erythroleukemic K562 TfR2(+) cells as a model, we observed that agents that enhance c-Myc expression, such as iron, determine a decrease of TfR2 expression, while molecules that induce a decreased c-Myc expression, such as the iron chelator desferoxamine or the kinase inhibitor ST 1571, induce an enhanced TfR2 expression. On the other hand, we have evaluated a possible effect of hypoxia and nitric oxide on TfR2 expression in erythroleukemia K526 and hepatoma HepG2 cells, providing evidence that: (i) agents inducing cellular hypoxia, such as CoCl(2), elicited a marked upmodulation of TfR1, but a downmodulation of TfR2 expression; (ii) NO(+) donors, such as sodium nitroprusside (SNP), induced a moderate decrease of TfR1, associated with a marked decline of TfR2 expression; (iii) NO donors, such as S-Nitroso-N-Acetylpenicillamine (SNAP), induced a clear increase of TfR1, associated with a moderate upmodulation of TfR2 expression. The ensemble of these observations suggests that in cancer cell lines TfR2 expression can be modulated through stimuli similar to those known to act on TfR1 and these findings may have important implications for our understanding of the role of TfR2 in the regulation of iron homeostasis.
Calzolari
Alessia
A
Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Finisguerra
Veronica
V
Oliviero
Isabella
I
Deaglio
Silvia
S
Mariani
Gualtiero
G
Malavasi
Fabio
F
Testa
Ugo
U
D015703:Antigens, CD / Q000096:biosynthesis* / Q000187:drug effects; D016587:Antimutagenic Agents / Q000494:pharmacology; D001052:Apoferritins / Q000096:biosynthesis; D001549:Benzamides; D015687:Cell Hypoxia / Q000187:drug effects / Q000502:physiology; D045744:Cell Line, Tumor; D003035:Cobalt / Q000494:pharmacology; D003676:Deferoxamine / Q000494:pharmacology; D006801:Humans; D000068877:Imatinib Mesylate; D007501:Iron / Q000494:pharmacology; D035942:Iron Regulatory Protein 2 / Q000096:biosynthesis; D009569:Nitric Oxide / Q000378:metabolism; D020030:Nitric Oxide Donors / Q000494:pharmacology; D009599:Nitroprusside / Q000494:pharmacology; D010396:Penicillamine / Q000031:analogs & derivatives / Q000494:pharmacology; D010879:Piperazines; D016271:Proto-Oncogene Proteins c-myc / Q000187:drug effects / Q000378:metabolism*; D011743:Pyrimidines / Q000494:pharmacology; D011990:Receptors, Transferrin / Q000096:biosynthesis* / Q000187:drug effects; D017262:Siderophores / Q000494:pharmacology
D015703:Antigens, CD; D016587:Antimutagenic Agents; D001549:Benzamides; C068126:CD71 antigen; C489427:MYC protein, human; D020030:Nitric Oxide Donors; D010879:Piperazines; D016271:Proto-Oncogene Proteins c-myc; D011743:Pyrimidines; D011990:Receptors, Transferrin; C110881:S-nitro-N-acetylpenicillamine; D017262:Siderophores; C503640:TFR2 protein, human; D009599:Nitroprusside; D009569:Nitric Oxide; D003035:Cobalt; D000068877:Imatinib Mesylate; D001052:Apoferritins; D007501:Iron; D035942:Iron Regulatory Protein 2; C018021:cobaltous chloride; D010396:Penicillamine; D003676:Deferoxamine